Lactobacillus casei as Next Generation Probiotics

Unlike the harmful bacteria that make you sick, probiotics like Lactobacillus casei (L. casei) are good for your body. Creative Biolabs now provides a full range of probiotic drug development services to help health.

Introduction of L. casei

L. casei is a species in the genus Lactobacillus, which widely exists in the human urinary system and mouth. It has been reported that this particular type of lactic acid bacteria has a wide range of pH and temperature, and supplements the growth of L. acidophilus, which has various benefits for human health and is often used as a probiotic. It is a Gram-positive, inactive, nonporous, and catalase-negative bacterium. Cells are 0.7-1.1 × 2.0-4.0 μm rods, usually with square ends, appearing alone, in pairs or chains. The cell wall contains l-Lys-d-Asp peptidoglycan and polysaccharides, which determine the serological specificity (B or C) of rhamnose or glucose galactose content. The G + C content of DNA was 45-47%.

Lactobacillus casei - Creative Biolabs

The benefit of L. casei in Diseases

L. casei is widely used as probiotics or synbiotic supplements to improve clinical efficacy. At present, the results of some clinical trials have evaluated the efficacy of this probiotic. L. casei has achieved positive effects in some digestive tract diseases, chronic infectious diseases, obesity, and depression patients.

Obesity and metabolic syndrome are associated with inflammation. Intestinal flora seems to play an important role in the development of inflammatory and metabolic syndrome in obesity. The regulation of intestinal flora by probiotics has been shown to positively affect inflammation and metabolic disorders in animal studies.

L. casei can reduce metabolic endotoxemia by changing intestinal flora composition and intestinal permeability, thus improving neutrophil function and insulin resistance in obese patients.

The interaction between symbiotic bacteria and the intestinal immune system is an important factor in the occurrence and development of inflammatory bowel disease (IBD). To study the effect of isolated symbiotic bacteria (e.g. E. coli) on mucosal immune response in patients with IBD may help to better understand the pathophysiological mechanism of the disease. Some researchers took ileum samples from Crohn's disease (CD) patients and incubated mucosal explants with L. casei or its genomic DNA to evaluate the tissue expression of key pro-inflammatory cytokines and chemokines. The results showed that living L. casei could inhibit the pro-inflammatory effect of E. coli on CD inflammatory mucosa by specifically downregulating the key inflammatory mediators.

  • Upper Respiratory Infections

Virus-induced upper respiratory infection is one of the most common human health problems. In addition to the pain caused by the disease, these infections also bring a huge burden to society. In the analysis of the specificity of L. casei, it is found that it has a positive effect on the prevention of upper respiratory tract infection.

  • Liver Diseases

Changes in the balance of intestinal microbiota in healthy individuals may lead to the development of many liver diseases, including cirrhosis complications. The use of probiotics to restore and regulate intestinal flora is a potential therapeutic strategy. In the treatment of piglet liver, L. casei can reduce the liver injury induced by lipopolysaccharide by reducing proinflammatory cytokines and improving antioxidant capacity, which indicates that L. casei has the potential to be recommended as a treatment for liver diseases.

Schematic illustration of multifarious mechanisms involved in liver diseases and probiotic influences. Fig.1 Schematic illustration of multifarious mechanisms involved in liver diseases and probiotic influences. (Fooladi, 2013)

Drug Discovery Service for L. casei

To obtain high-quality probiotics products, we need to consider all aspects and comprehensive evaluation. For example:

  • Evaluation of cell viability: the number of microorganisms used in probiotic products is crucial to the effectiveness of the product. Evaluating cell viability under simulated actual application conditions is the key to probiotic selection;
  • Identification of host bacteria interaction: the key criteria for probiotics selection are to understand the colonization and protection mechanism of strains in vivo;
  • Improving final biomass production: developing new fermentation strategies to improve final biomass production is the core of bypassing one of the bottlenecks encountered in the production of starter, probiotics, and medical devices.

Creative Biolabs is a leader in the drug development of probiotics. With excellent service quality and a professional knowledge system, we are committed to providing the best and most comprehensive probiotic development services to customers from all over the world. If you are interested in our drug discovery service of L. casei, please feel free to contact us.

Reference

  1. Fooladi, A. A. I., et al. Probiotic as a novel treatment strategy against liver disease. Hepatitis monthly. 2013, 13(2).

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Live Biotherapeutics Drug Discovery

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Contact us

Contact us

Copyright © 2021 Creative Biolabs. All Rights Reserved.

Inquiry Basket